Fintel reports that on May 13, 2026, UBS upgraded their outlook for Corcept Therapeutics (NasdaqCM:CORT) from Neutral to Buy.
Analyst Price Forecast Suggests 34.38% Upside
As of April 28, 2026, the average one-year price target for Corcept Therapeutics is $68.75/share. The forecasts range from a low of $44.44 to a high of $115.50. The average price target represents an increase of 34.38% from its latest reported closing price of $51.16 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Corcept Therapeutics is 511MM, a decrease of 33.59%. The projected annual non-GAAP EPS is 1.22.
What is the Fund Sentiment?
There are 376 funds or institutions reporting positions in Corcept Therapeutics. This is an decrease of 329 owner(s) or 46.67% in the last quarter. Average portfolio weight of all funds dedicated to CORT is 0.11%, an increase of 57.70%. Total shares owned by institutions decreased in the last three months by 6.23% to 83,864K shares. 
The put/call ratio of CORT is 0.63, indicating a bullish outlook.
What are Other Shareholders Doing?
Ingalls & Snyder holds 7,195K shares representing 6.70% ownership of the company. In its prior filing, the firm reported owning 7,698K shares , representing a decrease of 6.99%. The firm decreased its portfolio allocation in CORT by 56.05% over the last quarter.
Renaissance Technologies holds 5,759K shares representing 5.36% ownership of the company. In its prior filing, the firm reported owning 6,089K shares , representing a decrease of 5.74%. The firm decreased its portfolio allocation in CORT by 53.47% over the last quarter.
Vanguard Portfolio Management holds 4,821K shares representing 4.49% ownership of the company.
Vanguard Capital Management holds 4,077K shares representing 3.80% ownership of the company.
Parallel Advisors holds 3,879K shares representing 3.61% ownership of the company. In its prior filing, the firm reported owning 3,871K shares , representing an increase of 0.20%. The firm decreased its portfolio allocation in CORT by 58.09% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
